Table 1.
Studies characteristics
| STUDY | SITE | POPULATION | INTERVENTION (ITT/PP) | COMPARISON (ITT/PP) | OUTCOMES |
| Regev et al[34] | 1 | 29 to 86 y | Pico-Salax (1+1+1)/0 sachets | New-Meroken® 3/0 L | Bowel cleansing quality |
| Israel | + (200/h for 16h)/0 mL of water | Cecal intubation | |||
| ITT: 68 | + clear liquid diet | + clear liquid diet | General discomfort | ||
| PP: 68 | 39/39 | 29/29 | Medication Intake | ||
| Adverse events | |||||
| Lawrance et al[35] | 1 | 18 to 75 y | Pico® (1+1)/0 sachets for morning procedure or | ColonLytely® 4/0 L for morning procedure or | Bowel cleansing quality |
| Australia | |||||
| Pico 1/1 sachets for afternoon procedure | ColonLytely® 4/0 L for afternoon procedure | ||||
| + liquid | + clear liquid 2/0 | ||||
| ITT: 634 | + low residue diet | 284/279 | Medication Intake | ||
| PP: 625 | 171/169 | ||||
| CB fleet® (45+45)/0 mL | |||||
| + (750+750)/0 mL of water for morning procedure or | Mucosal inflammation | ||||
| CB fleet® 45/45 mL | |||||
| + 750/750 mL of water for afternoon procedure | |||||
| + low residue diet | |||||
| 179/177 | |||||
| Kao et al[36] | 1 | 18 to 75 y | SPMC (1+1+MC)/0 sachets for morning procedure or | PEG 4/0 L for morning procedure or | Bowel cleansing quality |
| Canada | |||||
| SPMC (1+1)/MC sachets for afternoon procedure | PEG 2/2 L for afternoon procedure | Bowel cleansing quality according to the procedure time | |||
| ITT: 834 | + liquid | + liquid | Tolerability | ||
| PP: 790 | + clear liquid diet | + clear liquid diet | |||
| 194/194 | 218/210 | Adherence | |||
| NaP 45/45/0 mL for morning procedure or | PEG 2/0 L + bisacodyl 20/0 mg for morning procedure or | Sleeping hours | |||
| NaP 0/45/45 mL for afternoon procedure | PEG 0/2 L + bisacodyl 20/0 mg for afternoon procedure | Willingness to reuse | |||
| + liquid | + liquid | Safety | |||
| + clear liquid diet | + clear liquid diet | ||||
| 164/164 | 214/210 | Ischemic colitis | |||
| Katz et al[15] | 12 | 18 to 80 y | Prepopik® (1+1)/0 sachets | Half-Lytely e bisacodyl Tablets® 2/0 L | Bowel cleansing quality |
| USA | |||||
| + (1200+720)/0 mL of liquid | + 10/0 mg bisacodyl | Acceptability | |||
| Tolerability | |||||
| ITT: 603 | + clear liquid diet | + clear liquid diet | Medication Intake | ||
| PP: 598 | Ease to use medication | ||||
| 300/296 | 303/302 | General experience | |||
| Taste | |||||
| Willingness to reuse | |||||
| Adverse events | |||||
| Manes et al[37] | 3 | 18 to 85 y | CitraFleet® (1+1)/0 sachets | Moviprep® 2/0 L | Bowel cleansing quality |
| Italy | |||||
| + 3/0 L of liquid for morning procedure or | + 1/0 L of liquid for morning procedure or | Bowel cleansing quality of right colon | |||
| ITT: 293 | CitraFleet® 1/1 sachets | Moviprep® 1/1 L | Polyps detected | ||
| PP: 285 | + 1.5/1.5 L of liquid for afternoon procedure | + 500/500 mL of liquid for afternoon procedure | Acceptance | ||
| + low-fiber diet | + low-fiber diet | Tolerability | |||
| 145/140 | 148/145 | Adherence | |||
| Adverse events | |||||
| Rex et al[15] | 10 | 18 to 80 y | Prepopik® 1/1 sachets | Half-Lytely e bisacodyl Tablets® 2/0 L | Bowel cleansing quality |
| USA | |||||
| + 1200/720 mL of liquid | + bisacodyl 10/0 mg | Acceptability | |||
| + clear liquid diet | Tolerability | ||||
| ITT: 608 | + clear liquid diet | Ease to use medication | |||
| PP: 601 | Medication Intake | ||||
| Taste | |||||
| NA/305 | NA/298 | Willingness to reuse medication | |||
| Adverse events | |||||
| Colonoscopy before | |||||
| Jeon et al[38] | 1 | 20 to 80 y | Picolight powder® (1+1)/1 sachet | Coolprep powder® 1/1 L | Bowel cleansing quality |
| South Korea | |||||
| + (1+1)/1 L of water | + 500/500 mL of water | Cecal intubation | |||
| + low-fiber diet | + low-fiber diet | Withdrawal time | |||
| ITT: 430 | ADR | ||||
| PP: 388 | PDR | ||||
| Tolerability | |||||
| 215/195 | 215/193 | Satisfaction | |||
| Adverse events | |||||
| Kang et al[39] | 1 | 18 to ou mais | Picolight® 0/(1+1) | Colyte® 2/2 L | Bowel cleansing quality |
| South Korea | |||||
| + 0/≥ 1 L of water | + low-fiber diet | Tolerability | |||
| ITT: 197 | + low-fiber diet | 99/99 | Adverse events | ||
| PP: 197 | 98/98 | Sleep time quantity | |||
| PDR | |||||
| ADR | |||||
| Kim et al[40] | 1 | 18 to 75 y | SPMC 1/1 sachets | PEG 0/4 L | Bowel cleansing quality |
| South Korea | |||||
| + 1/1 L of liquid | Adherence | ||||
| + low-fiber diet | + low-fiber diet | Medication Intake | |||
| ITT: 200 | 50/50 | 50/50 | |||
| PP: 200 | SPMC (1+1)/1 sachets | PEG 2/2 L | Tolerability | ||
| + (1+1)/1 L of liquid | Taste | ||||
| + low-fiber diet | + low-fiber diet | Biochemical changes | |||
| 50/50 | 50/50 | Adverse events | |||
| Kim et al[41] | 1 | 18 to 80 y | Picolight (1+1)/0 sachets | Standard PEG 4/0 L | Acceptability |
| South Korea | + 2L of water | Adherence to instructions | |||
| ITT: 194 | + bisacodyl 10/0 mg | + bisacodyl 10/0 mg | Bowel cleansing quality | ||
| PP: 184 | + low-fiber diet (ZeroCol) | + semi-fluid diet | Adverse events | ||
| 97/94 | 97/90 | Willingness to reuse medication | |||
| Leitao et al[28] | 3 | 18 to 80 y | CitraFleet® 1/1 sachets | Enddealk® 2/1L | Bowel cleansing quality |
| Norway | |||||
| + 2/2 L of water | + 0/1 L of liquid | Tolerability | |||
| ITT: 368 | + no-grains diet | + diet without crops | Adherence | ||
| PP: 368 | PDR | ||||
| 179/179 | 189/189 | Cecal intubation time | |||
| Cecal intubation | |||||
| Kim et al[29] | 13 | 20 to 75 y | sachets | Standard PEG 2/2 L | Bowel cleansing quality |
| South Korea | |||||
| + 2/2 L of water | no bisacodyl | Satisfaction | |||
| + bisacodyl 10/0 mg | + low-fiber diet | Tolerability | |||
| + low-fiber diet | Medication Intake | ||||
| ITT: 387 | 193/181 | 194 / 184 | Ease to use | ||
| PP: 365 | Taste | ||||
| Willingness to reuse | |||||
| Adverse events | |||||
| Munsterman et al[30] | 1 | 18 to 80 y | Picoprep® 1/1 sachets for morning procedure or | Kleanprep® 3/1 L for morning procedure or | Bowel cleansing quality |
| Netherlands | |||||
| ITT: 173 | Picoprep® 1/1 sachets for afternoon procedure | Kleanprep® 2/2 L for afternoon procedure | |||
| PP: 172 | + 2/2 L of water | + additional liquid | Tolerability | ||
| + low-fiber diet | + low-fiber diet | ||||
| 88/87 | 85/85 | ||||
| Pohl et al[31] | 17 | 40 to 80 y | CitraFleet® (1+1)/0 sachets | Moviprep® 1/1 L | Patients with at least one polyp or flat lesion |
| Germany | |||||
| ITT: 399 | + 250mL/h of water after sachet | + 500/500 mL of liquid | Patients with at least one adenoma | ||
| PP: 398 | Cancer detection rate | ||||
| + fibers restriction diet | + fibers restriction diet | Flat lesion detection rate | |||
| NA/197 | NA/201 | Advanced lesions detection rate | |||
| Yoo et al[32] | 1 | 18 to 80 y | Picolight® 1/1 sachets | Coolprep® 1/1 L | Bowel cleansing quality |
| South Korea | |||||
| + 1/1 L of water | + 500/500 mL of water | Bubble score | |||
| ITT: 200 | + low-fiber diet | + low-fiber diet | Tolerability | ||
| PP: 200 | |||||
| 100/100 | 100/100 | Satisfaction | |||
| Kojecky et al[33] | 3 | 18 to 99 y | Picoprep® 2/0 sachets | Fortrans™ 4/0 L | Length of preparation |
| Czech Republic | + 2L of water | 94/102 | |||
| ITT: 612 | 92/102 | Fortrans™ 3/1 L | Time to colonoscopy | ||
| 87/102 | |||||
| PP: 584 | OR | Moviprep™ 2/0 L | |||
| + 1/0 L of fluids | |||||
| Picoprep® 1/1 sachets | 96/102 | Bowel cleansing quality | |||
| + 1/1 L of water | |||||
| 86/102 | Moviprep™ 1/1 | ||||
| + 0.5/0.5 L of fluids | |||||
| 93/102 | Tolerability score | ||||
| + low residue diet | + low residue diet |
* In intervention and control columns, slash separates different days and plus sign separates different doses on the same day; * ITT: number of randomized patients (intention to treat); * PP: number of treated patients (per protocol); * NR: not reported in full-text; * PDR: polyp detection rate; * ADR: adenoma detection rate.